List of Excipients in Branded Drug ARZERRA

Arzerra Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Arzerra, the intravenous formulation of ofatumumab, uses a conventional liquid monoclonal-antibody excipient system centered on buffering, tonicity control, surfactant protection, and amino-acid stabilization. Its commercial opportunity is no longer concentrated in branded CLL sales. The stronger opportunities are contract manufacturing, hospital-ready presentation, analytical comparability, excipient supply, and development of follow-on anti-CD20 products.

What excipients are used in Arzerra?

Arzerra contains ofatumumab at 20 mg/mL in a sterile concentrate for intravenous infusion. The US product is supplied in 100 mg/5 mL and 1,000 mg/50 mL single-use vials.[1]

The labeled inactive ingredients are:

Excipient	Primary formulation function
L-arginine	Protein stabilization and solubility support
Sodium citrate	Buffering and pH control
Citric acid monohydrate	Buffering and pH adjustment
Polysorbate 80	Limits surface adsorption and aggregation
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle

The formulation has an approximate pH of 6.5.[1] This is a standard liquid-antibody architecture. It avoids lyophilization, which reduces reconstitution steps but increases dependence on cold-chain control, container-closure integrity, and long-term aggregation management.

What role does polysorbate 80 play in Arzerra?

Polysorbate 80 reduces adsorption of ofatumumab to vial, tubing, syringe, and infusion-contact surfaces. It also limits interfacial stress during handling and dilution.

Its main risks are oxidation, hydrolysis, peroxide formation, and lot-to-lot variability. These degradation pathways can generate protein oxidation or subvisible particles. A follow-on manufacturer would therefore need to control:

• Polysorbate concentration and purity
• Peroxide content
• Fatty-acid composition
• Oxidative degradation during storage
• Compatibility with infusion bags and administration sets

Polysorbate 80 remains commercially attractive because it is widely accepted in biologics manufacturing and familiar to regulators. Its limitations create opportunities for alternative surfactants, including polysorbate 20, poloxamers, and newer low-peroxide surfactant grades, but any substitution would require extensive comparability and stability work.

Why is L-arginine included?

L-arginine can improve protein solubility and reduce self-association. In a concentrated antibody formulation, it may support a lower aggregation profile without relying on high concentrations of sugar or polyol excipients.

For an Arzerra-like product, arginine concentration is a critical formulation variable. Excessive arginine can affect osmolality, viscosity, protein conformation, and infusion tolerability. A commercial developer would evaluate arginine against histidine, acetate, phosphate, sucrose, trehalose, and amino-acid combinations.

What is the Arzerra formulation and presentation strategy?

Arzerra is supplied as a ready-to-dilute concentrate rather than a ready-to-infuse bag. The product is administered after dilution in an approved intravenous solution under the prescribing information.[1]

Arzerra presentation advantages

The concentrate format provides several commercial benefits:

1. It reduces fill volume relative to a ready-to-use infusion.
2. It supports two vial strengths for induction and maintenance dosing.
3. It permits centralized manufacturing of a single liquid formulation.
4. It avoids the reconstitution errors associated with lyophilized antibodies.

The disadvantages are operational. Hospitals must dilute the product, manage aseptic preparation, hold the dose under specified conditions, and administer a large-volume infusion. Those steps increase pharmacy labor and create opportunities for product loss.

A hospital-ready formulation could therefore compete through:

• Lower-volume infusion
• Premixed bags
• Closed-system transfer compatibility
• Reduced preparation time
• Longer in-use stability after dilution
• Lower discard rates
• More convenient vial sizes

Any such change would be a pharmaceutical development program, not a simple packaging modification. Changes to concentration, container, dilution medium, or administration route can affect product quality, safety, and clinical performance.

What formulation patents protect Arzerra?

Arzerra is a biologic product, so its exclusivity profile differs from that of a conventional small-molecule drug. The primary regulatory protection is associated with the biologics license and related patent rights, not a standard ANDA-based generic pathway.

Relevant patent categories may include:

• Ofatumumab composition-of-matter claims
• Anti-CD20 antibody sequence claims
• Antibody production-cell-line claims
• CLL treatment methods
• Combination treatment claims
• Dosing-regimen claims
• Liquid formulation claims
• Container and administration claims
• Manufacturing and purification methods

The exact enforceability of these rights depends on claim scope, priority dates, prosecution history, terminal disclaimers, maintenance fees, and jurisdiction. A reliable patent conclusion requires a live family-level review of US, European, UK, Japanese, Chinese, and other national records.

Does Arzerra have Orange Book-listed patents?

Arzerra is regulated as a biologic under a BLA rather than as a conventional small-molecule product approved through an NDA. The Orange Book is therefore not the principal source for its biologic patent and exclusivity analysis.[2]

For a follow-on ofatumumab product, relevant sources include:

• FDA Purple Book information
• FDA BLA and approval-history records
• USPTO patent records
• International patent-family databases
• Court dockets and settlement filings
• FDA guidance on biosimilar development

An absence of a conventional Orange Book listing does not establish that no enforceable patent rights exist.

When did Arzerra lose exclusivity?

Arzerra’s exclusivity must be separated into regulatory exclusivity, patent exclusivity, and practical commercial exclusivity.

Protection type	Relevance to Arzerra
BLA regulatory exclusivity	Applies under biologic exclusivity rules and depends on the product’s approval history
Patent exclusivity	Depends on individual patent claims and expiration dates
Pediatric exclusivity	Applies only if granted for the relevant product
Orphan exclusivity	Depends on the indication and designation
Commercial exclusivity	Can persist after formal expiration if development and manufacturing barriers remain high

FDA approved Arzerra in 2009 for previously untreated chronic lymphocytic leukemia in certain patients and later expanded its indications.[1] The drug’s commercial position was later weakened by the emergence of other anti-CD20 treatments and by the development of ofatumumab as Kesimpta for multiple sclerosis.

The key business point is that formal loss of exclusivity does not automatically produce a biosimilar launch. An anti-CD20 biosimilar developer still faces clinical, analytical, manufacturing, regulatory, and market-access barriers.

What generic or biosimilar entry risks exist for Arzerra?

A conventional generic cannot rely on an ANDA to copy Arzerra because ofatumumab is a monoclonal antibody. A follow-on developer would generally pursue a biosimilar pathway or another biologics pathway, depending on the jurisdiction and product strategy.[3]

Main biosimilar barriers

The principal barriers are:

• Demonstrating analytical similarity across multiple quality attributes
• Matching glycosylation and charge variants
• Controlling aggregation and particle levels
• Establishing comparable target binding and cell-killing activity
• Reproducing the clinical route and dosing context
• Securing commercial-scale mammalian-cell manufacturing
• Managing residual patent and litigation risk
• Obtaining reimbursement and formulary access

Anti-CD20 antibodies also require careful characterization of complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, B-cell depletion, and Fc-mediated functions. A product that matches primary sequence but differs materially in glycosylation or effector function may face a more difficult regulatory assessment.

What would a biosimilar launch scenario look like?

A plausible follow-on sequence would be:

1. Analytical and formulation screening.
2. Cell-line and process development.
3. Reference-product sourcing across jurisdictions.
4. Nonclinical comparability and functional assays.
5. Clinical pharmacology or a confirmatory study, depending on the regulator.
6. Patent certification, notice, or litigation.
7. Manufacturing validation and launch preparation.
8. Negotiated market entry or launch after relevant rights expire.

The commercial launch may target hospital CLL treatment first. The larger strategic value could come from platform use of the anti-CD20 molecule, although indication extrapolation would be regulator-specific.

What commercial opportunities exist in Arzerra excipients?

The most immediate opportunity is not a new excipient. It is supplying higher-quality, biologics-grade versions of familiar excipients with better control of impurities and degradation.

High-value excipient opportunities

Low-peroxide polysorbate 80

Polysorbate 80 suppliers can differentiate through:

• Lower initial peroxide levels
• Controlled hydrolysis profile
• Reduced particulate formation
• Tighter fatty-acid distribution
• Improved lot consistency
• Enhanced analytical documentation

This is relevant to liquid monoclonal antibodies because surfactant degradation can affect product quality during long-term storage.

Pharmaceutical-grade L-arginine

L-arginine suppliers can compete on:

• Low endotoxin burden
• Low bioburden
• Controlled metals
• Consistent optical purity
• Low particulate load
• Supply continuity
• Regional manufacturing redundancy

For biologics, excipient qualification can become a supply-chain bottleneck even when the ingredient itself is commercially common.

Citrate-buffer systems

Citrate suppliers and formulation developers can pursue:

• Lower-concentration buffers
• Improved pH stability
• Reduced interaction with container materials
• Compatibility with high-concentration antibodies
• Lower injection-site or infusion-related burden where applicable

Citrate is well established, but its performance depends on concentration, pH, ionic strength, and interactions with the protein and packaging system.

Alternative surfactants

Poloxamer 188, polysorbate 20, and other surfactants may offer a route around polysorbate degradation. Their commercial value would depend on maintaining ofatumumab stability while reducing particles and oxidation products.

Substitution is difficult because surfactants can change:

• Protein unfolding behavior
• Subvisible particle generation
• Container adsorption
• Filter recovery
• Dilution stability
• Freeze-thaw performance
• Compatibility with administration equipment

What manufacturing and intellectual-property barriers affect commercial entry?

The formulation itself is only one part of the entry barrier. A competitive product must establish a controlled process for:

• Mammalian-cell expression
• Protein A capture
• Viral inactivation and clearance
• Polishing chromatography
• Virus filtration
• Concentration and buffer exchange
• Sterile filtration
• Aseptic vial filling
• Cold-chain distribution

Ofatumumab is a glycoprotein antibody. Process changes can affect glycan distribution, charge heterogeneity, oxidation, aggregation, and Fc-mediated activity. A biosimilar manufacturer therefore cannot assume that the Arzerra excipient list is sufficient to reproduce the reference product.

IP exposure may arise from process patents even after core antibody claims expire. Patent review should cover manufacturing methods, cell culture, purification, formulation, use, and delivery. Geographic differences are material. A patent may be expired in one country, pending in another, and enforceable in a third.

How does Arzerra compare with Kesimpta?

Arzerra and Kesimpta both contain ofatumumab but address different commercial and formulation strategies.

Attribute	Arzerra	Kesimpta
Active ingredient	Ofatumumab	Ofatumumab
Primary route	Intravenous infusion	Subcutaneous injection
Historical primary use	Chronic lymphocytic leukemia	Relapsing forms of multiple sclerosis
Presentation	Concentrate in single-use vials	Prefilled injection presentation
Administration model	Hospital or infusion-center workflow	Patient self-administration or outpatient use
Commercial differentiation	Oncology dosing and infusion management	Convenience and chronic outpatient treatment
Excipient priority	Dilution stability and infusion compatibility	Injection tolerability, device compatibility, and shelf stability

The commercial lesson is significant: the same antibody can support different value propositions when the route, indication, device, dosing frequency, and care setting change. For Arzerra, the most defensible commercial opportunities are linked to oncology workflow and manufacturing efficiency. For Kesimpta-like development, the opportunity shifts toward high-concentration subcutaneous formulations, device integration, and patient usability.

Which companies are challenging Arzerra commercially?

The competitive set includes:

• Other anti-CD20 antibodies used in hematologic malignancies
• Small-molecule CLL therapies, including BTK and BCL-2 inhibitors
• Follow-on or biosimilar anti-CD20 programs
• Ofatumumab products in different indications
• Hospital-administered biologics with more convenient dosing

Rituximab and obinutuzumab are the most direct established biologic comparators in B-cell malignancies. Ibrutinib-class and venetoclax-based regimens compete on treatment sequencing, oral administration, and disease-control strategy rather than on excipient design.

Commercial competition therefore depends less on the individual inactive ingredients and more on total treatment economics: infusion time, pharmacy preparation, adverse-event management, dosing schedule, and reimbursement.

What is the revenue exposure associated with Arzerra?

Arzerra’s historical revenue exposure is lower than the revenue base associated with Kesimpta. Public company reporting should be reviewed by product and indication because ofatumumab sales may be reported under the newer multiple-sclerosis product rather than Arzerra.

For an Arzerra-related commercial program, revenue should be modeled against:

• Remaining treated CLL population
• Use of competing oral targeted therapies
• Hospital purchasing contracts
• Biosimilar price erosion
• Infusion-center capacity
• Product discontinuation or limited-market status
• Manufacturing cost per vial
• Vial wastage and dose utilization

Excipient cost is usually a small portion of total biologic cost of goods. Its strategic value comes from reducing batch failures, extending shelf life, improving dilution stability, and enabling a commercially superior presentation.

Key Takeaways

• Arzerra uses a liquid IV formulation containing L-arginine, citrate buffer components, polysorbate 80, sodium chloride, and water for injection.
• Polysorbate 80 control is the most important excipient-quality issue because degradation can drive oxidation and particulate risk.
• L-arginine supports protein solubility and stabilization but must be optimized against osmolality, viscosity, and aggregation.
• The product is a biologic, so biosimilar and patent analysis is more relevant than conventional ANDA and Orange Book analysis.
• The strongest excipient opportunities involve low-peroxide surfactants, biologics-grade arginine, supply redundancy, and improved dilution stability.
• Commercial differentiation is more likely through hospital workflow, ready-to-use presentation, reduced waste, and manufacturing reliability than through a new inactive ingredient alone.
• Kesimpta demonstrates how the same antibody can support a materially different commercial strategy through subcutaneous delivery and outpatient use.
• A follow-on product faces analytical, manufacturing, regulatory, patent, and reimbursement barriers even if the public excipient list is replicated.

FAQs

Can Arzerra be reformulated with polysorbate 20?

Potentially, but the substitution would require full comparability, stability, particle, adsorption, and functional testing. Polysorbate 20 is not interchangeable with polysorbate 80 solely because both are nonionic surfactants.

Is Arzerra a lyophilized antibody?

No. Arzerra is supplied as a sterile liquid concentrate for intravenous infusion, which avoids reconstitution but requires controlled dilution and cold-chain handling.[1]

Are Arzerra excipients patentable?

Individual excipients such as sodium chloride or citrate are generally not protectable as new chemical entities. Patent value may arise from specific concentrations, combinations, pH ranges, stability profiles, container systems, or methods of use.

Could a biosimilar use different excipients from Arzerra?

Yes. A biosimilar does not necessarily need to duplicate every inactive ingredient. The alternative formulation must support comparable product quality and must satisfy the applicable regulatory requirements for safety, efficacy, and manufacturing control.

Does Kesimpta create a direct Arzerra formulation opportunity?

It creates a platform opportunity rather than a direct formulation copy opportunity. Kesimpta’s subcutaneous route requires different development priorities, including injection volume, viscosity, local tolerability, device compatibility, and patient-use stability.

References

1. U.S. Food and Drug Administration. (n.d.). Arzerra (ofatumumab) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
4. European Medicines Agency. (n.d.). Arzerra: European public assessment report and product information.
5. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.